TY  - JOUR
AU  - Guntschnig, Sonja
AU  - Antoniadis, Vasilis
AU  - Falamic, Slaven
AU  - Kovačević, Tijana
AU  - Kurczewska-Michalak, Marta
AU  - Miljković, Branislava
AU  - Olearova, Anna
AU  - Sviestina, Inese
AU  - Szucs, Attila
AU  - Bampali, Konstantina
AU  - Tiszai, Zita
AU  - Volmer, Daisy
AU  - Wiela-Hojeńska, Anna
AU  - Fialova, Daniela
AU  - Vlcek, Jiri
AU  - Stuhec, Matej
AU  - Hogg, Anita
AU  - Scott, Michael
AU  - Stewart, Derek
AU  - Mair, Alpana
AU  - Ravera, Silvia
AU  - Lery, François-Xavier
AU  - Kardas, Przemysław
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4984
AB  - Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.
PB  - Frontiers Media SA
T2  - Frontiers in Pharmacology
T1  - Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes
VL  - 14
DO  - 10.3389/fphar.2023.1244151
ER  - 

@article{
author = "Guntschnig, Sonja and Antoniadis, Vasilis and Falamic, Slaven and Kovačević, Tijana and Kurczewska-Michalak, Marta and Miljković, Branislava and Olearova, Anna and Sviestina, Inese and Szucs, Attila and Bampali, Konstantina and Tiszai, Zita and Volmer, Daisy and Wiela-Hojeńska, Anna and Fialova, Daniela and Vlcek, Jiri and Stuhec, Matej and Hogg, Anita and Scott, Michael and Stewart, Derek and Mair, Alpana and Ravera, Silvia and Lery, François-Xavier and Kardas, Przemysław",
year = "2023",
abstract = "Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.",
publisher = "Frontiers Media SA",
journal = "Frontiers in Pharmacology",
title = "Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes",
volume = "14",
doi = "10.3389/fphar.2023.1244151"
}

Guntschnig, S., Antoniadis, V., Falamic, S., Kovačević, T., Kurczewska-Michalak, M., Miljković, B., Olearova, A., Sviestina, I., Szucs, A., Bampali, K., Tiszai, Z., Volmer, D., Wiela-Hojeńska, A., Fialova, D., Vlcek, J., Stuhec, M., Hogg, A., Scott, M., Stewart, D., Mair, A., Ravera, S., Lery, F.,& Kardas, P.. (2023). Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. in Frontiers in Pharmacology
Frontiers Media SA., 14.
https://doi.org/10.3389/fphar.2023.1244151

Guntschnig S, Antoniadis V, Falamic S, Kovačević T, Kurczewska-Michalak M, Miljković B, Olearova A, Sviestina I, Szucs A, Bampali K, Tiszai Z, Volmer D, Wiela-Hojeńska A, Fialova D, Vlcek J, Stuhec M, Hogg A, Scott M, Stewart D, Mair A, Ravera S, Lery F, Kardas P. Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. in Frontiers in Pharmacology. 2023;14.
doi:10.3389/fphar.2023.1244151 .

Guntschnig, Sonja, Antoniadis, Vasilis, Falamic, Slaven, Kovačević, Tijana, Kurczewska-Michalak, Marta, Miljković, Branislava, Olearova, Anna, Sviestina, Inese, Szucs, Attila, Bampali, Konstantina, Tiszai, Zita, Volmer, Daisy, Wiela-Hojeńska, Anna, Fialova, Daniela, Vlcek, Jiri, Stuhec, Matej, Hogg, Anita, Scott, Michael, Stewart, Derek, Mair, Alpana, Ravera, Silvia, Lery, François-Xavier, Kardas, Przemysław, "Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes" in Frontiers in Pharmacology, 14 (2023),
https://doi.org/10.3389/fphar.2023.1244151 . .

TY  - JOUR
AU  - Brkić, Jovana
AU  - Fialova, Daniela
AU  - Okuyan, Betul
AU  - Kummer, Ingrid
AU  - Šesto, Sofija
AU  - Capiau, Andreas
AU  - Ortner Hadžiabdić, Maja
AU  - Tachkov, Konstantin
AU  - Bobrova, Veera
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4345
PB  - Nature Research
T2  - Scientific Reports
T1  - Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis
VL  - 12
IS  - 1
DO  - 10.1038/s41598-022-25155-9
ER  - 

@article{
author = "Brkić, Jovana and Fialova, Daniela and Okuyan, Betul and Kummer, Ingrid and Šesto, Sofija and Capiau, Andreas and Ortner Hadžiabdić, Maja and Tachkov, Konstantin and Bobrova, Veera",
year = "2022",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis",
volume = "12",
number = "1",
doi = "10.1038/s41598-022-25155-9"
}

Brkić, J., Fialova, D., Okuyan, B., Kummer, I., Šesto, S., Capiau, A., Ortner Hadžiabdić, M., Tachkov, K.,& Bobrova, V.. (2022). Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis. in Scientific Reports
Nature Research., 12(1).
https://doi.org/10.1038/s41598-022-25155-9

Brkić J, Fialova D, Okuyan B, Kummer I, Šesto S, Capiau A, Ortner Hadžiabdić M, Tachkov K, Bobrova V. Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis. in Scientific Reports. 2022;12(1).
doi:10.1038/s41598-022-25155-9 .

Brkić, Jovana, Fialova, Daniela, Okuyan, Betul, Kummer, Ingrid, Šesto, Sofija, Capiau, Andreas, Ortner Hadžiabdić, Maja, Tachkov, Konstantin, Bobrova, Veera, "Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis" in Scientific Reports, 12, no. 1 (2022),
https://doi.org/10.1038/s41598-022-25155-9 . .

TY  - JOUR
AU  - Brkić, Jovana
AU  - Fialova, Daniela
AU  - Okuyan, Betul
AU  - Kummer, Ingrid
AU  - Šesto, Sofija
AU  - Capiau, Andreas
AU  - Ortner Hadžiabdić, Maja
AU  - Tachkov, Konstantin
AU  - Bobrova, Veera
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4286
AB  - We aimed to systematically review the prevalence of potentially inappropriate prescribing (PIP) in older adults in Central and Eastern Europe (CEE) in all care settings. We searched Embase and MEDLINE (up to June 2019) and checked the reference lists of the included studies and relevant reviews. Eligible studies used validated explicit or implicit tools to assess the PIP prevalence in older adults in CEE. All study designs were considered, except case‒control studies and case series. We assessed the risk of bias using the Joanna Briggs Institute Prevalence Critical Appraisal Tool and the certainty of evidence using the GRADE approach. Meta-analysis was inappropriate due to heterogeneity in the outcome measurements. Therefore, we used the synthesis without meta-analysis approach—summarizing effect estimates method. This review included twenty-seven studies with 139,693 participants. Most studies were cross-sectional and conducted in high-income countries. The data synthesis across 26 studies revealed the PIP prevalence: the median was 34.6%, the interquartile range was 25.9–63.2%, and the range was 6.5–95.8%. The certainty of this evidence was very low due to the risk of bias, imprecision, and inconsistency. These findings show that PIP is a prevalent issue in the CEE region. Further well-designed studies conducted across countries are needed to strengthen the existing evidence and increase the generalizability of findings.
PB  - Nature Research
T2  - Scientific Reports
T1  - Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis
VL  - 12
IS  - 1
DO  - 10.1038/s41598-022-19860-8
ER  - 

@article{
author = "Brkić, Jovana and Fialova, Daniela and Okuyan, Betul and Kummer, Ingrid and Šesto, Sofija and Capiau, Andreas and Ortner Hadžiabdić, Maja and Tachkov, Konstantin and Bobrova, Veera",
year = "2022",
abstract = "We aimed to systematically review the prevalence of potentially inappropriate prescribing (PIP) in older adults in Central and Eastern Europe (CEE) in all care settings. We searched Embase and MEDLINE (up to June 2019) and checked the reference lists of the included studies and relevant reviews. Eligible studies used validated explicit or implicit tools to assess the PIP prevalence in older adults in CEE. All study designs were considered, except case‒control studies and case series. We assessed the risk of bias using the Joanna Briggs Institute Prevalence Critical Appraisal Tool and the certainty of evidence using the GRADE approach. Meta-analysis was inappropriate due to heterogeneity in the outcome measurements. Therefore, we used the synthesis without meta-analysis approach—summarizing effect estimates method. This review included twenty-seven studies with 139,693 participants. Most studies were cross-sectional and conducted in high-income countries. The data synthesis across 26 studies revealed the PIP prevalence: the median was 34.6%, the interquartile range was 25.9–63.2%, and the range was 6.5–95.8%. The certainty of this evidence was very low due to the risk of bias, imprecision, and inconsistency. These findings show that PIP is a prevalent issue in the CEE region. Further well-designed studies conducted across countries are needed to strengthen the existing evidence and increase the generalizability of findings.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis",
volume = "12",
number = "1",
doi = "10.1038/s41598-022-19860-8"
}

Brkić, J., Fialova, D., Okuyan, B., Kummer, I., Šesto, S., Capiau, A., Ortner Hadžiabdić, M., Tachkov, K.,& Bobrova, V.. (2022). Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis. in Scientific Reports
Nature Research., 12(1).
https://doi.org/10.1038/s41598-022-19860-8

Brkić J, Fialova D, Okuyan B, Kummer I, Šesto S, Capiau A, Ortner Hadžiabdić M, Tachkov K, Bobrova V. Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis. in Scientific Reports. 2022;12(1).
doi:10.1038/s41598-022-19860-8 .

Brkić, Jovana, Fialova, Daniela, Okuyan, Betul, Kummer, Ingrid, Šesto, Sofija, Capiau, Andreas, Ortner Hadžiabdić, Maja, Tachkov, Konstantin, Bobrova, Veera, "Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis" in Scientific Reports, 12, no. 1 (2022),
https://doi.org/10.1038/s41598-022-19860-8 . .

TY  - CONF
AU  - Šesto, Sofija
AU  - Tadić, Ivana
AU  - Marinković, Valentina
AU  - Odalović, Marina
AU  - Tasić, L.
AU  - Brkić, Jovana
AU  - Fialova, Daniela
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4356
PB  - Springer
C3  - International Journal of Clinical Pharmacy
T1  - Self-reported medication adherence in older patients
VL  - 43
IS  - 3
SP  - 814
EP  - 815
DO  - 10.1007/s11096-021-01279-2
ER  - 

@conference{
author = "Šesto, Sofija and Tadić, Ivana and Marinković, Valentina and Odalović, Marina and Tasić, L. and Brkić, Jovana and Fialova, Daniela",
year = "2021",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Self-reported medication adherence in older patients",
volume = "43",
number = "3",
pages = "814-815",
doi = "10.1007/s11096-021-01279-2"
}

Šesto, S., Tadić, I., Marinković, V., Odalović, M., Tasić, L., Brkić, J.,& Fialova, D.. (2021). Self-reported medication adherence in older patients. in International Journal of Clinical Pharmacy
Springer., 43(3), 814-815.
https://doi.org/10.1007/s11096-021-01279-2

Šesto S, Tadić I, Marinković V, Odalović M, Tasić L, Brkić J, Fialova D. Self-reported medication adherence in older patients. in International Journal of Clinical Pharmacy. 2021;43(3):814-815.
doi:10.1007/s11096-021-01279-2 .

Šesto, Sofija, Tadić, Ivana, Marinković, Valentina, Odalović, Marina, Tasić, L., Brkić, Jovana, Fialova, Daniela, "Self-reported medication adherence in older patients" in International Journal of Clinical Pharmacy, 43, no. 3 (2021):814-815,
https://doi.org/10.1007/s11096-021-01279-2 . .

TY  - JOUR
AU  - Fialova, Daniela
AU  - Laffon, Blanca
AU  - Marinković, Valentina
AU  - Tasić, Ljiljana
AU  - Doro, Peter
AU  - Soos, Gyongyver
AU  - Mota, Jorge
AU  - Dogan, Soner
AU  - Brkić, Jovana
AU  - Teixeira, Joao Paulo
AU  - Valdiglesias, Vanessa
AU  - Costa, Solange
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3360
AB  - IntroductionThe importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the age-blind approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches.MethodologyA narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise).ResultsOlder patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of somenonpharmacological strategies is highly underestimated in older adultsin contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinicalstudies.ConclusionSeveral regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat
VL  - 75
IS  - 4
SP  - 451
EP  - 466
DO  - 10.1007/s00228-018-2603-5
ER  - 

@article{
author = "Fialova, Daniela and Laffon, Blanca and Marinković, Valentina and Tasić, Ljiljana and Doro, Peter and Soos, Gyongyver and Mota, Jorge and Dogan, Soner and Brkić, Jovana and Teixeira, Joao Paulo and Valdiglesias, Vanessa and Costa, Solange",
year = "2019",
abstract = "IntroductionThe importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the age-blind approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches.MethodologyA narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise).ResultsOlder patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of somenonpharmacological strategies is highly underestimated in older adultsin contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinicalstudies.ConclusionSeveral regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat",
volume = "75",
number = "4",
pages = "451-466",
doi = "10.1007/s00228-018-2603-5"
}

Fialova, D., Laffon, B., Marinković, V., Tasić, L., Doro, P., Soos, G., Mota, J., Dogan, S., Brkić, J., Teixeira, J. P., Valdiglesias, V.,& Costa, S.. (2019). Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 75(4), 451-466.
https://doi.org/10.1007/s00228-018-2603-5

Fialova D, Laffon B, Marinković V, Tasić L, Doro P, Soos G, Mota J, Dogan S, Brkić J, Teixeira JP, Valdiglesias V, Costa S. Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat. in European Journal of Clinical Pharmacology. 2019;75(4):451-466.
doi:10.1007/s00228-018-2603-5 .

Fialova, Daniela, Laffon, Blanca, Marinković, Valentina, Tasić, Ljiljana, Doro, Peter, Soos, Gyongyver, Mota, Jorge, Dogan, Soner, Brkić, Jovana, Teixeira, Joao Paulo, Valdiglesias, Vanessa, Costa, Solange, "Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat" in European Journal of Clinical Pharmacology, 75, no. 4 (2019):451-466,
https://doi.org/10.1007/s00228-018-2603-5 . .

TY  - JOUR
AU  - Fialova, Daniela
AU  - Brkić, Jovana
AU  - Laffon, Blanca
AU  - Reissigova, Jindra
AU  - Gresakova, Silvia
AU  - Dogan, Soner
AU  - Doro, Peter
AU  - Tasić, Ljiljana
AU  - Marinković, Valentina
AU  - Valdiglesias, Vanessa
AU  - Costa, Solange
AU  - Kostriba, Jan
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3264
AB  - Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.
PB  - Sage Publications Ltd, London
T2  - Therapeutic Advances in Drug Safet
T1  - Applicability of EU(7)-PIM criteria in cross-national studies in European countries
VL  - 10
DO  - 10.1177/2042098619854014
ER  - 

@article{
author = "Fialova, Daniela and Brkić, Jovana and Laffon, Blanca and Reissigova, Jindra and Gresakova, Silvia and Dogan, Soner and Doro, Peter and Tasić, Ljiljana and Marinković, Valentina and Valdiglesias, Vanessa and Costa, Solange and Kostriba, Jan",
year = "2019",
abstract = "Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.",
publisher = "Sage Publications Ltd, London",
journal = "Therapeutic Advances in Drug Safet",
title = "Applicability of EU(7)-PIM criteria in cross-national studies in European countries",
volume = "10",
doi = "10.1177/2042098619854014"
}

Fialova, D., Brkić, J., Laffon, B., Reissigova, J., Gresakova, S., Dogan, S., Doro, P., Tasić, L., Marinković, V., Valdiglesias, V., Costa, S.,& Kostriba, J.. (2019). Applicability of EU(7)-PIM criteria in cross-national studies in European countries. in Therapeutic Advances in Drug Safet
Sage Publications Ltd, London., 10.
https://doi.org/10.1177/2042098619854014

Fialova D, Brkić J, Laffon B, Reissigova J, Gresakova S, Dogan S, Doro P, Tasić L, Marinković V, Valdiglesias V, Costa S, Kostriba J. Applicability of EU(7)-PIM criteria in cross-national studies in European countries. in Therapeutic Advances in Drug Safet. 2019;10.
doi:10.1177/2042098619854014 .

Fialova, Daniela, Brkić, Jovana, Laffon, Blanca, Reissigova, Jindra, Gresakova, Silvia, Dogan, Soner, Doro, Peter, Tasić, Ljiljana, Marinković, Valentina, Valdiglesias, Vanessa, Costa, Solange, Kostriba, Jan, "Applicability of EU(7)-PIM criteria in cross-national studies in European countries" in Therapeutic Advances in Drug Safet, 10 (2019),
https://doi.org/10.1177/2042098619854014 . .

TY  - CONF
AU  - Fialova, Daniela
AU  - Vysinova, Tereza
AU  - Gresakova, Silvia
AU  - Laffon-Deusdad, Blanca
AU  - Doro, Peter
AU  - Dogan, Soner
AU  - Costa, Solange
AU  - Valdiglesias, Vanessa
AU  - Brkić, Jovana
AU  - Marinković, Valentina
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2950
PB  - Springer, Dordrecht
C3  - International Journal of Clinical Pharmacy
T1  - Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative
VL  - 39
IS  - 1
SP  - 310
EP  - 311
DO  - 10.1007/s11096-016-0404-4
ER  - 

@conference{
author = "Fialova, Daniela and Vysinova, Tereza and Gresakova, Silvia and Laffon-Deusdad, Blanca and Doro, Peter and Dogan, Soner and Costa, Solange and Valdiglesias, Vanessa and Brkić, Jovana and Marinković, Valentina",
year = "2017",
publisher = "Springer, Dordrecht",
journal = "International Journal of Clinical Pharmacy",
title = "Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative",
volume = "39",
number = "1",
pages = "310-311",
doi = "10.1007/s11096-016-0404-4"
}

Fialova, D., Vysinova, T., Gresakova, S., Laffon-Deusdad, B., Doro, P., Dogan, S., Costa, S., Valdiglesias, V., Brkić, J.,& Marinković, V.. (2017). Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative. in International Journal of Clinical Pharmacy
Springer, Dordrecht., 39(1), 310-311.
https://doi.org/10.1007/s11096-016-0404-4

Fialova D, Vysinova T, Gresakova S, Laffon-Deusdad B, Doro P, Dogan S, Costa S, Valdiglesias V, Brkić J, Marinković V. Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative. in International Journal of Clinical Pharmacy. 2017;39(1):310-311.
doi:10.1007/s11096-016-0404-4 .

Fialova, Daniela, Vysinova, Tereza, Gresakova, Silvia, Laffon-Deusdad, Blanca, Doro, Peter, Dogan, Soner, Costa, Solange, Valdiglesias, Vanessa, Brkić, Jovana, Marinković, Valentina, "Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative" in International Journal of Clinical Pharmacy, 39, no. 1 (2017):310-311,
https://doi.org/10.1007/s11096-016-0404-4 . .